HMGA2 promotes epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via transforming growth factor-β/small mothers against decapentaplegic 2

Table 2 Univariate analyses of overall survival in intrahepatic cholangiocarcinoma patients

Variables	Factors	β	SE	Wald	P value	HR (95%CI)
Gender	Female/male	-0.221	0.312	0.502	0.479	0.802 (0.435-1.478)
Age	< 60/≥ 60	0.092	0.297	0.096	0.756	1.097 (0.612-1.964)
TBIL (μmol/L)	< 26/≥ 26	0.011	0.322	0.001	0.972	1.011 (0.538-1.901)
GGT (U/L)	< 60/≥ 60	0.430	0.477	0.810	0.368	1.537 (0.603-3.915)
ALP (U/L)	< 125/≥ 125	0.547	0.478	1.310	0.252	1.728 (0.677-4.406)
CEA (ng/mL)	< 3.4/≥ 3.4	0.119	0.299	0.158	0.691	1.126 (0.626-2.025)
CA125 (U/mL)	< 35/≥ 35	-0.373	0.304	1.506	0.220	0.689 (0.380-1.249)
CA199 (U/mL)	< 27/≥ 27	0.335	0.314	1.140	0.286	1.398 (0.756-2.585)
Hepatitis B	Negative/positive	-0.294	0.443	0.440	0.507	0.745 (0.313-1.776)
Hepatitis C	Negative/positive	0.299	0.535	0.313	0.576	1.349 (0.473-3.846)
Bile duct stones	No/yes	-0.208	0.296	0.493	0.483	0.812 (0.454-1.452)
Differentiation degree	Well, moderately/poorly	0.834	0.322	6.706	0.010	2.302 (1.225-4.328)
Tumor size	< 3/≥ 3	0.279	0.317	0.776	0.378	1.322 (0.711-2.460)
Bile duct type	Small/large	0.302	0.296	1.043	0.307	1.353 (0.757-2.417)
Surgical margin	Negative/positive	1.114	0.544	4.194	0.041	3.045 (1.049-8.840)
Vascular invasion	No/yes	0.684	0.310	4.869	0.027	1.982 (1.079-3.639)
Perineural invasion	No/yes	0.072	0.296	0.059	0.808	1.075 (0.602-1.920)
Lymph node metastasis	No/yes	0.282	0.361	0.610	0.435	1.326 (0.653-2.693)
Postoperative chemotherapy	No/yes	0.147	0.327	0.203	0.652	1.159 (0.610-2.199)
HMGA2	Negative/positive	0.790	0.323	5.977	0.014	2.203 (1.170-4.148)

HR: Hazard ratio; CI: Confidence interval; TBIL: Total bilirubin; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; CEA: Carcinoembryonic antigen; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199.